Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report

BACKGROUND: Immune checkpoint inhibitors have shown clinically significant antitumor efficacy and have been approved for the treatment of various kinds of advanced malignancies. On the other hand, these immunotherapies show unique adverse events, termed “immune-related adverse events,” which are dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Onishi, Sachiyo, Tajika, Masahiro, Bando, Hideaki, Matsubara, Yuki, Hosoda, Waki, Muro, Kei, Niwa, Yasumasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689984/
https://www.ncbi.nlm.nih.gov/pubmed/33239098
http://dx.doi.org/10.1186/s13256-020-02541-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689984/
https://www.ncbi.nlm.nih.gov/pubmed/33239098
http://dx.doi.org/10.1186/s13256-020-02541-3

Ejemplares similares